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Introduction: HIV reduces fertility through biological and social
pathways, and antiretroviral treatment (ART) can ameliorate these
effects. In northern Malawi, ART has been available since 2007 and
lifelong ART is offered to all pregnant or breastfeeding HIV-
positive women.
Methods: Using data from the Karonga Health and Demographic
Surveillance Site in Malawi from 2005 to 2014, we used total and
age-specific fertility rates and Cox regression to assess associations
between HIV and ART use and fertility. We also assessed temporal
trends in in utero and breastfeeding HIV and ART exposure among
live births.
Results: From 2005 to 2014, there were 13,583 live births during
approximately 78,000 person years of follow-up of women aged 15–
49 years. The total fertility rate in HIV-negative women decreased
from 6.1 [95% confidence interval (CI): 5.5 to 6.8] in 2005–2006 to
5.1 (4.8–5.5) in 2011–2014. In HIV-positive women, the total
fertility rate was more stable, although lower, at 4.4 (3.2–6.1) in
2011–2014. In 2011–2014, compared with HIV-negative women,
the adjusted (age, marital status, and education) hazard ratio was 0.7
(95% CI: 0.6 to 0.9) and 0.8 (95% CI: 0.6 to 1.0) for women on ART
for at least 9 months and not (yet) on ART, respectively. The crude
fertility rate increased with duration on ART up to 3 years before
declining. The proportion of HIV-exposed infants decreased, but the
proportion of ART-exposed infants increased from 2.4% in 2007–
2010 to 3.5% in 2011–2014.
Conclusions: Fertility rates in HIV-positive women are stable in
the context of generally decreasing fertility. Despite a decrease in
HIV-exposed infants, there has been an increase in ART-
exposed infants.
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INTRODUCTION
Fertility in many countries of sub-Saharan Africa (SSA)
is falling,1 although the rate of decline has been slower than
most other world regions, and there is some evidence to
suggest that fertility decline has plateaued in some countries.2
Fertility is influenced by childbearing desires, contraceptive
use, and maternal health. In SSA, increases in women’s
education and employment opportunities, access to contracep-
tion, and changes in societal and individual opinions regarding
delaying childbearing in unstable or uncertain periods are
thought to have influenced fertility trends.3 In many SSA
countries, the HIV epidemic has had negative impacts on
health and family stability with consequences for fertility.4–6
The effect of HIV on fertility is complex. HIV and
fertility are positively associated in adolescents, as women
who have unprotected sex have higher risk of both HIV
acquisition and pregnancy.7 However, older HIV-positive
women have lower fertility rates than HIV-negative
women.4,7 HIV infection has been shown through biological
pathways to reduce the ability to conceive and bear a live
child.8–12 Social and behavioral factors are also related to
lower fertility in HIV-positive women because of altered
childbearing desires11,13–16 and likelihood of being in a rela-
tionship.17 In Malawi and other high HIV-prevalence coun-
tries, widespread availability of antiretroviral treatment
(ART) has removed many of the biological barriers to fertility
by improving health and survival of women and their
partners,18,19 which has been shown to increase people’s
desire for children,20,21 although this may not correlate with
actual fertility.22 There is, however, still uncertainty surround-
ing the impact of increased access to ART on fertility in HIV-
positive women.23
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Malawi has adopted a public health approach24 to its
HIV epidemic with sector-wide policies to maximize ART
uptake in HIV-positive people, including Option B+25: from
July 2011, all pregnant and breastfeeding women were
eligible for lifelong ART regardless of immunological status,
and in 2016, universal ART eligibility was introduced so all
HIV-positive people should be offered ART at the time of
testing.26 Before Option B+, prevention of mother-to-child
transmission programmes involved HIV testing for pregnant
women and short courses of ART, taken until completion of
breastfeeding.27 Since 2011, the guidelines in Malawi have
promoted provider-initiated family planning but specifically
stated that “Health workers should not actively discourage
pregnancy” in HIV-positive women.28
Studying trends in fertility is important, as it enables
long-term planning for services required for pregnant women
and their children at various stages in their lives. In Malawi,
infants born to HIV-positive mothers should be monitored
until aged 24 months, which presents a burden to an already
stretched health service, and retention in this programme is
not always optimal.29 Reducing the number of children born
with HIV would reduce the burden on the health system once
they were older, but there is little evidence regarding the long-
term effects of exposure to ART in utero or through
breastfeeding, especially in rural African contexts.30 If the
expansion of the ART programme is accompanied by
increasing fertility in women on ART, there will be
a concomitant increase in the number of infants requiring
monitoring and testing for HIV and an increasing number of
ART-exposed children whose future health needs are
currently uncertain.
In this study, we use data from a rural longitudinal
cohort in northern Malawi to explore temporal fertility trends
and the association of HIV infection and ART availability
with fertility. We also describe temporal trends in HIV and
ART exposure in infants.
METHODS
Population and Data
Population
The Karonga Health and Demographic Surveillance
Site (HDSS), established in 2002, captures information on
births, deaths, and in- and out-migrations in a population of
approximately 39,000 people (including 9000 women aged
15–49) living in a 150 km2 rural area of northern Malawi.31
The HDSS has also collected socioeconomic information,
including highest attained education level and marital status,
from annual surveys since 2007. In 2007–2008, the adult HIV
prevalence was 6.3% in males and 8.5% in females, and
estimated ART coverage was 48% in males and 65% in
females in 2008–2010.32
HIV Test Data
Within the HDSS, population-level HIV testing and
counseling in adults 15 years and older were done in multiple
serosurveys, starting with randomly selected clusters in 2005–
2006 and followed by 4 successive HIV serosurveys across
the whole population, from 2007 to 2011. Interviewers asked
about previous HIV testing (available from several providers
in the area), including the timing and result of the most recent
test (positive, negative or unknown). Each serosurvey used
a standardized rapid test protocol; results were immediately
available to the participant33 and the vast majority (.90%) of
people consented to be informed of their result. Within the
HDSS, HIV testing (with disclosure to participants) has also
been offered in some smaller research studies conducted from
1988 onward. We included these HIV test data in this
analysis, if the study was population representative and not
limited to select groups (eg, clinically symptomatic people).
For our analysis, we assigned HIV-positive status from
1 year before their first positive test date (or from the
midpoint between the last negative test and the first positive,
if that interval was 1 year or shorter). To be comparable with
the HIV-positive women, we assigned women as HIV-
negative from 1 year before their first negative test date
(self-report or study), and up to 4 years after their last
negative test date (because of relatively low incidence rates in
the area and length of time since the last serosurvey) unless
they had a subsequent positive test during this time. All other
time was classified as unknown. Infants were categorized as
HIV exposed if their mothers were identified as HIV positive
at any time up to 1 year after their birth (assuming that they
would have been breastfed for at least 1 year).
ART Use Data
ART was available at the main hospital (which is 70 km
from the HDSS area and largely inaccessible to the HDSS
population) from June 2005, at the rural hospital within the
HDSS area from September 2006, and at smaller clinics in the
area from October 2010. Data on uptake of HIV services were
collected through links with local clinics: by identifying and
tracking cohorts of consenting people initiated on ART and
capturing current and previous ART usage.34 We assigned
women as not (yet) on ART from 1 year before their first
positive test (ie, from the point we assigned them as HIV
positive) up to their first ART start date (self-reported or
clinic) or up to 2 years after the last date they are known to
have never taken ART. We assigned women as on ART from
their first ART start date (self-reported or clinic) up to their
last ART stop date (self-reported or clinic) or up to 3 months
after the last date they are known to still be taking ART
(assuming they took their final prescription). Infants were
categorized as ART exposed if their mothers were on ART at
any time up to 1 year after their birth (assuming that they
would have been breastfed for at least 1 year).
Statistical Methods
We conducted a longitudinal analysis, including person
years for the period of follow-up for the entire population of
women aged 15–49 and all live births (with multiple births
contributing separately) born to these women between 2005
and 2014. We examined fertility trends over 3 periods of
ART availability: 2005–2006 (no/little ART in the HDSS
area), 2007–2010 (ART roll-out), and 2011–2014 (ART
widely available) in the following ways:
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• We calculated age-specific fertility rates by HIV/ART
status. We then used these age-specific rates to calculate
the total fertility rate (TFR): a summary measure of the
average number of children that would be born per woman
if they were to complete childbearing years experiencing
the current age-specific rates. We also used Cox pro-
portional hazards regression models to compare fertility
rates in HIV-positive women on ART or not (yet) on ART
with those of HIV-negative women, with adjustment for
age (in 5-year age bands), marital status (never married,
married, divorced, and widowed), and educational level
(none, primary standards 1–3, primary standards 4–7,
primary completed, 2 years of secondary, and 4 years of
secondary). Option B+ has resulted in relatively healthy
women initiating ART because of pregnancy; to avoid this
artificially raising the apparent fertility of women on ART,
we only included women who had been on ART for at least
9 months (excluding 102 births where the mother started
ART during pregnancy and 486.3 person years). Sub-
sequent births to Option B+ women were included.
• We calculated crude and age-specific fertility rates by
number of years on ART (excluding less than 1 year
because of the above described issue of women starting
ART in pregnancy and combining 4 years and above
because of the small number of births in younger women).
• We calculated the number and proportion of infants who
were HIV and ART exposed in the 3 periods and the
proportion exposed to ART from the first trimester of
pregnancy until at least delivery (calculated by estimating
the conception date as 9 months before the birth date).
RESULTS
From 2005 to 2014, there were 13,583 live births during
approximately 78,000 person years of follow-up of women aged
15–49. Overall, the TFR was 5.2 [95% confidence interval (CI):
4.9 to 5.4], declining from 6.0 (5.4–6.6) in 2005–2006 to 4.6
(4.3–4.9) in 2011–2014 (Table 1). The highest crude fertility
rates were in the 20–24 year age group [270.7 per 1000 person
years (262.5–279.2)], in married women [226.2 per 1000
(221.8–230.7)], and in women with 4–7 years of education
(excluding unknown education category) [182.6 per 1000
(177.6–187.7)] (Table 1). There were 9391 births to HIV-
negative women and 626 births to HIV-positive women (158 on
ART for at least 9 months, 294 not on ART, 102 started ART
during pregnancy, and 72 unknown) (Table 1). Of the 1294
women reported to be HIV positive during the analysis, 738
(57.0%) had their first HIV-positive test date derived from clinic
or HIV test data and 556 (43.0%) from self-reported data. Of the
745 women reported to be on ART at any point during the
analysis, 380 (51.0%) had the first ART initiation date derived
from clinic data and 365 (49.0%) from self-reported data.
Fertility Rates in HIV-positive vs. HIV-
negative Women
From 2005–2006 to 2011–2014, there was a downward
trend in the TFR of HIV-negative women [6.1 (4.6–8.1) to
5.1 (4.8–5.5)]. In HIV-positive women, there was an increase
from 3.7 (1.7–8.4) in 2005–2006 to 4.3 (3.2–6.0) in 2007–
2010. However, it remained stable up to 2011–2014 when it
was 4.4 (3.2–6.1) (Table 2). The TFR in women with
unknown HIV status decreased more sharply than in the
HIV-negative women, from 6.1 (5.5–6.8) to 2.8 (2.1–4.0);
this was due to a fall in the number of births born to women
with unknown HIV status (669 in 2007–2010 vs. 371 in
2010–2014), which was not reflected in a decrease in the
number of person years (4300.9 in 2007–2010 vs. 4919.6
in 2010–2014).
Fertility Rates in HIV-positive Women on ART
vs. HIV-positive Women Not on ART
The pattern of age-specific fertility rates in women on
ART for at least 9 months changed from 2007–2010 to 2011–
2014. In the earlier period, rates in younger women were
lower than those of women not on ART, whereas in the later
period, they were higher and more similar to those of HIV-
negative women. However, CIs were wide: the fertility rate in
the 20–24 year group on ART at least 9 months was 146.5 per
1000 (47.3–454.3) in 2007–2010 and 316.0 per 1000 (175.0–
570.6) in 2011–2014. Rates in older women in both periods
were similar in women on and not (yet) on ART (Fig. 1).
The TFR in HIV-positive women on ART for at least 9
months in 2011–2014 was 3.7 (2.2–7.1), which was similar to
that of women not on ART [3.8 (2.1–7.3)] (Table 2).
Compared with HIV-negative women, HIV-positive women
experienced lower adjusted hazards for a live birth throughout
follow-up, and there was little evidence of a difference
between women on ART for at least 9 months and not (yet)
on ART: in 2011–2014, the adjusted hazard ratios were 0.7
(0.6–0.9) and 0.8 (0.6–1.0), respectively (Table 3). The TFR
in women who started ART during pregnancy was high and
increased over time. The rates for women with unknown ART
status were higher than those known not to be on ART;
however, the numbers of births and person years in both these
categories were small (Table 2).
Fertility Rates in HIV-positive Women by
Years on ART
Crude fertility rates increased with years since ART
initiation, from 65.4 per 1000 (46.5–91.9) in women on ART
for 1 year, to a peak of 94.0 per 1000 (95% CI: 66.8 to 132.3)
in women who had been on ART for 3 years. The rate in
women on ART for 4 or more years was lower at 64.8 per
1000 (49.4–85.0). This pattern was observed in the 20–29
year age group, and, at lower levels, in the 30–49 year group
(Table 4).
Exposure to ART in Utero and Breastfeeding
The proportion of infants who were HIV exposed
decreased slightly from 5.8% (313/5435) in 2007–2010 to
5.2% (271/5255) in 2011–2014. The proportion exposed to
ART increased, however, from 2.4% (83/5435) to 3.5% (185/
5255). In 2011–2014, 2.5% (n = 134) of all live births were
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reported to have been exposed to ART from the first trimester
of pregnancy up to delivery.
DISCUSSION
Our findings from rural Malawi show that from 2005 to
2014, during increasing availability of ART, the TFR declined
overall and in HIV-negative women, while remaining stable and
lower in HIV-positive women. There was a suggestion of an
increase in fertility levels in younger women on ART, and
fertility levels increased with time on ART (up to peak at 3 years
since initiation); however, there was little overall difference in
fertility in women on ART for at least 9 months and women not
(yet) on ART. Nonetheless, despite lack of evidence for
increasing fertility in HIV-positive women at the population
level, the proportion of infants exposed to ART has increased.
The overall decrease in fertility in our HDSS is
consistent with the level of fertility decline shown in the
TABLE 1. Number of Births, Person Years, Crude Fertility Rate, and Total Fertility Rate by Demographic and HIV/ART Variables,
2005–2014
Variable/Level No. of Births Person years
Fertility Rate per 1000
Person years (95% CI) Total Fertility Rate
Overall 13,583 77,726.5 174.8 (171.8 to 177.7) 5.2 (4.9–5.4)
Age group, yrs
15–19 2930 18,095.7 161.9 (156.2 to 167.9)
20–24 4035 14,903.4 270.7 (262.5 to 279.2)
25–29 3206 13,285.5 241.3 (233.1 to 249.8)
30–34 2030 11,116.8 182.6 (174.8 to 190.7)
35–39 1060 8490.4 124.8 (117.6 to 132.6)
40–44 301 6547.9 46.0 (41.1 to 51.5)
45–49 21 5286.7 4.0 (2.6 to 6.1)
Marital status
Never married 710 13,118.6 54.1 (50.3 to 58.3) 1.9 (1.3–2.9)
Married 9800 43,325.2 226.2 (221.8 to 230.7) 7.0 (6.7–7.4)
Divorced 96 2447.6 39.2 (32.1 to 47.9) 2.2 (1.2–6.0)
Widowed 608 6294.6 96.6 (89.2 to 104.6) 3.3 (2.7–4.1)
Unknown 2369 12,540.3 188.9 (181.5 to 196.7) 5.6 (5.1–6.2)
Highest education level*
None 132 1307.2 101.0 (85.1 to 119.8) 3.8 (2.5–6.0)
1–3 yr primary 546 3600.9 151.6 (139.4 to 164.9) 5.6 (4.6–6.9)
4–7 yr primary 5068 27,754.0 182.6 (177.6 to 187.7) 5.6 (5.3–6.1)
Primary completed 3565 20,701.7 172.2 (166.6 to 178.0) 5.2 (4.8–5.7)
JCE completed 2010 11,077.7 181.4 (173.7 to 189.6) 4.7 (4.1–5.4)
MSCE completed 1056 7161.9 147.4 (138.8 to 156.6) 3.9 (3.3–4.8)
Unknown 1206 6123.2 197.0 (186.1 to 208.4) 5.6 (4.8–6.5)
Period
2005–2006 2893 14,058.7 205.8 (198.4 to 213.4) 6.0 (5.4–6.6)
2007–2010 5435 29,751.7 182.7 (177.9 to 187.6) 5.4 (5.0–5.8)
2011–2014 5255 33,916.1 154.9 (150.8 to 159.2) 4.6 (4.3–4.9)
Time living in DSS area, yrs
,2 796 5032.7 158.2 (147.6 to 169.5) 4.9 (4.0–6.4)
,4 1497 9771.5 153.2 (145.6 to 161.2) 4.7 (4.0–5.5)
,6 1682 10,906.5 154.2 (147.0 to 161.8) 4.6 (4.0–5.4)
,8 1895 11,127.4 170.3 (162.8 to 178.1) 4.8 (4.2–5.5)
,10 7713 40,888.4 188.6 (184.5 to 192.9) 5.8 (5.5–6.2)
HIV/ART status
Negative 9391 50,529.8 185.9 (182.1 to 189.6) 5.4 (5.1–5.7)
Positive 626 6004.9 104.2 (96.4 to 112.7) 4.3 (3.5–5.3)
HIV positive, on ART at least 9 mo 158 2225.3 71.0 (60.8 to 83.0) 3.4 (2.2–5.9)
HIV positive, not (yet) on ART 294 2478.6 118.6 (105.8 to 133) 4.1 (3.1–5.6)
HIV positive, on ART less than 9 mo 102 486.3 209.7 (172.7 to 254.7) 10.5 (6.1–18.5)
HIV positive, unknown if on ART 72 814.7 88.4 (70.2 to 111.3) 3.7 (2.0–7.5)
Unknown 3566 21,191.8 168.3 (162.8 to 173.9) 5.2 (4.9–5.4)
*JCE, Junior certificate of education, taken after 2 years of secondary school; MSCE, Malawi school certificate of education, taken after completing secondary school (4 years).
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2010 Malawian Demographic and Health Survey, which
reported a TFR of 5.7 for the northern region, which compares
well to our figure of 5.4 in 2007–2010.35 Our findings of
increased fertility rates in HIV-positive women, although lower
than HIV-negative women during the era of widespread ART
availability, are consistent with those of a systematic review of
recently published studies.23 Evidence for an effect of duration
of ART on fertility is inconsistent: some studies report no
difference while others, including ours, report increasing
fertility rates with increased duration of ART.23
The lower fertility rates in younger women on ART in
the early period of ART availability in our data may be
because ART was initially provided to the sickest (and
presumably least fertile) individuals, with treatment extending
to individuals at an earlier stage of disease over time.
Recently, movement of HIV-positive women onto ART at
an earlier stage of disease, may explain the similar fertility
levels in women on ART and those not (yet) on ART (who
are yet to experience fertility effects of poor health).
Prolonged use of ART may itself have biological effects on
fertility which may explain the lower fertility levels of HIV-
positive women on ART compared with HIV-negative
women, and that even in younger women, fertility rates in
women on ART for 4 or more years are lower than those in
TABLE 2. Total Fertility Rate (and Number of Births) by HIV/ART Status and Year
2005–2006 2007–2010 2011–2014 Overall
Overall
TFR 6.0 5.4 4.6 5.2
95% CI 5.4 to 6.6 5.0 to 5.8 4.3 to 4.9 4.9 to 5.4
N 2893 5435 5255 13,583
Person years 14,058.7 29,751.7 33,916.1 77,726.5
Unknown
TFR 6.1 4.7 2.8 5.2
95% CI 5.5 to 6.8 3.9 to 5.7 2.1 to 4.0 4.8 to 5.7
N 2526 669 371 3566
Person years 11,971.4 4300.9 4919.6 21,191.8
Negative
TFR 6.1 5.7 5.1 5.4
95% CI 4.6 to 8.1 5.3 to 6.2 4.8 to 5.5 5.1 to 5.7
N 323 4455 4613 9391
Person years 1579.5 22,851.4 26,098.9 50,529.8
Positive
TFR 3.7 4.3 4.4 4.3
95% CI 1.7 to 8.4 3.2 to 6.0 3.2 to 6.1 3.5 to 5.3
N 44 311 271 626
Person years 507.9 2599.4 2897.6 6004.9
Positive
On ART at least 9 mo
TFR 1.3 3.2 3.7 3.4
95% CI 0.2 to 8.9 1.5 to 10.1 2.2 to 7.1 2.2 to 5.9
N 1 61 96 158
Person years 56.8 750.3 1418.3 2225.3
Not (yet) on ART
TFR 3.7 4.3 3.8 4.1
95% CI 1.5 to 9.8 3.0 to 6.3 2.1 to 7.3 3.1 to 5.6
N 32 199 63 294
Person years 332.5 1526.1 620.0 2478.6
On ART less than 9 mo
TFR 1.1 7.2 14.4 10.5
95% CI 0.2 to 5.6 2.5 to 28.0 7.6 to 27.6 6.1 to 18.5
N 3 37 62 102
Person years 80.0 229.4 177.0 486.3
Unknown ART
TFR 5.5 5.1 3.2 3.7
95% CI 1.3 to 27.6 1.8 to 18.2 1.5 to 8.2 2.0 to 7.5
N 8 14 50 72
Person years 38.6 93.7 682.3 814.7
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women on ART for 3 years. There is evidence to suggest that
some antiretroviral drugs have an adverse effect on gametes,8
although the effect of ART on male fertility is unclear.36,37
Early evidence on the impact of ART on birth outcomes is
inconsistent, with some studies showing no effect,38 whereas
others report increased preterm births.39
Fertility dynamics are also affected by childbearing
desires. Although evidence suggests that HIV-positive
women are less likely to want more children than HIV-
negative women,15 a study of 9 SSA countries found no
consistent pattern in changing fertility desires during increas-
ing coverage of ART.16 Although guidelines recommend that
HIV-positive women are not actively discouraged from
becoming pregnant,40 HIV-positive women in Malawi re-
ported no or discouraging discussions about childbearing with
health care workers41; this was confirmed by health care
workers in the same area who had mixed attitudes around
childbearing in HIV-positive women, with several actively
discouraging women.42 Community stigma against childbear-
ing in HIV-positive women may also explain why fertility
levels in HIV-positive women are not the same as those in
HIV-negative women.
Excluding women who start ART during pregnancy
was necessary to examine the effect of ART on fertility, as
many of these women would have only started ART because
of the pregnancy while healthy and the treatment would have
had no effect on the conception and live birth of the child (so
including them would inflate the observed effect of ART).
Nonetheless, it is also plausible that ART could have reduced
the chance of a miscarriage or, greater knowledge of ART
availability with the introduction of Option B+ may have
encouraged HIV-positive women/couples to bear a child
when otherwise they might not have; therefore, it is possible
that we have underestimated the effect of ART on fertility in
the population.
We found a reduction in the number of HIV-exposed
infants in recent years but, mainly due to the Option B+
policy, an increasing number of infants exposed to ART for
the entire pregnancy, which may have important implications
for the immediate and future health care needs of these
children. In Malawi, maternal HIV exposure remains an
important risk factor for infant morbidity and mortality,43 and
there is evidence that HIV exposed, but uninfected infants
have a higher risk of morbidity and mortality, perhaps
because of a greater likelihood of immune dysfunction and/
or low birth weight.39,44,45 Few adverse effects of in utero
ART have been found in developed settings,46–48 but the
short- and long-term effects of this exposure in populations
where pregnancy nutrition is suboptimal and mothers are
exposed to multiple infections are not well described.30,49,50
Longer follow-up with longitudinal studies of children
exposed to ART are needed to understand better the longer-
term sequelae of this early life exposure.
Incomplete data on HIV status and ART use is
a limitation of our study. We found different patterns in
fertility rates in women with unknown HIV status; however,
as their status is unknown to the research team, this group will
represent women who truly do not know their current HIV
status (never tested or received results from a test) and those
who know but were unwilling to disclose. In Malawi, opt-out
HIV testing is routinely offered in antenatal care; hence, it is
likely that women who have had a birth are more likely to
know their status than women who have not. These factors
make it difficult to interpret the fertility rates in women with
unknown status. Exclusion of women who started ART
during pregnancy further reduced our sample size in this
category, making interpretation of fertility trends a challenge:
TABLE 3. Hazard Ratio (HR) of Live Birth Event Controlling for
Age, Marital Status, and Education Level* in HIV-positive Women
Compared With HIV-negative Women by ART Usage and Year
Period
HIV positive, on
ART HR (95% CI)
HIV positive, Not (Yet) on
ART HR (95%CI)
2005–2006 0.3 (0.0 to 1.9) 0.7 (0.4 to 1.0)
2007–2010 0.8 (0.6 to 1.0) 0.8 (0.7 to 1.0)
2011–2014 0.7 (0.6 to 0.9) 0.8 (0.6 to 1.0)
*Categories used as in Table 1.
FIGURE 1. Age-specific fertility rates
by HIV/ART status and era of ART
availability. NB. Vertical lines show
confidence limits around each esti-
mate (capped at 500).
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for example, although there appeared to be an increase in
fertility rates in young HIV-positive women on ART, the
confidence limits were wide, which may have been because of
a small number of women in this category. However, use of
high-quality HDSS data means that we achieved high
ascertainment of all live births and use of HIV test data from
population-based HIV serosurveys, with high participation
rates (73%–83%), will have minimized the potential for
selection bias regarding HIV status. We do not capture
information on ART care from clinics outside the HDSS
area, so this could introduce bias if seeking care outside the
area was associated with fertility. Inaccuracies in ART start
and stop dates within clinic registers may have introduced
some misclassification of women’s exposure. We have
assigned women to be HIV positive for 1 year before their
first positive test because of the assumption that most people
will have seroconverted long before they test. One year could
be a conservative estimate and, with increasing access to HIV
testing, it is likely that the length of time between serocon-
version and testing positive will have changed over time.
Without access to gestational age at birth, we have assumed
each pregnancy to have lasted 9 months. This may have
resulted in exclusion of some women who started ART before
pregnancy but experienced a preterm birth, for which HIV
infection and ART increase risk, thereby further attenuating
fertility estimates in this group. Finally, although we attemp-
ted to control for factors known to be associated with HIV
status, ART usage, and fertility (education, marital status, and
age), some of these data were missing, and there may be other
unmeasured factors confounding the observed associations.
CONCLUSIONS
In rural Malawi, with widespread access to ART,
despite decreasing overall fertility levels, fertility rates in
HIV-positive women remain stable. Even without fertility
levels in HIV-positive women matching those of HIV-
negative women, the number of ART-exposed infants born
has increased and is likely to continue to do so with continued
implementation of the Option B+ mother-to-child transmis-
sion strategy. In this resource-constrained setting, determin-
ing and addressing the potential immediate and long-term
health care needs of an increasing number of ART-exposed
infants may be a challenge.
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